Drugs / LY3885125
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06007651 | Aug 2023 → Feb 2025 | NAFLD1, hyperlipidemia | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3885125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06007651 ↗ |
| Route | Subcutaneous | “Single ascending doses of LY3885125 administered subcutaneously (SC)” NCT06007651 ↗ |